Brokerages Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has been given an average rating of "Moderate Buy" by the seventeen analysts that are covering the company, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $25.56.

Several research analysts recently weighed in on the stock. Raymond James restated a "market perform" rating on shares of ACADIA Pharmaceuticals in a report on Thursday, October 10th. Needham & Company LLC reissued a "buy" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. StockNews.com lowered ACADIA Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 10,259 shares of ACADIA Pharmaceuticals stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $172,453.79. Following the completion of the sale, the chief financial officer now owns 53,302 shares of the company's stock, valued at $896,006.62. The trade was a 16.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider James Kihara sold 4,073 shares of the company's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $68,467.13. Following the completion of the transaction, the insider now owns 19,863 shares of the company's stock, valued at $333,897.03. The trade was a 17.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,661 shares of company stock valued at $414,551. Company insiders own 28.30% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Arizona State Retirement System lifted its stake in shares of ACADIA Pharmaceuticals by 2.2% in the 2nd quarter. Arizona State Retirement System now owns 29,983 shares of the biopharmaceutical company's stock valued at $487,000 after acquiring an additional 655 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in ACADIA Pharmaceuticals by 5.6% in the 2nd quarter. Commonwealth Equity Services LLC now owns 14,770 shares of the biopharmaceutical company's stock worth $240,000 after purchasing an additional 778 shares during the period. Quest Partners LLC lifted its position in ACADIA Pharmaceuticals by 42.3% in the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company's stock valued at $54,000 after purchasing an additional 1,047 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of ACADIA Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 1,066 shares during the period. Finally, Park Place Capital Corp purchased a new stake in shares of ACADIA Pharmaceuticals during the third quarter valued at approximately $25,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

ACADIA Pharmaceuticals Stock Performance

ACAD traded up $0.57 during midday trading on Friday, reaching $17.28. 1,082,441 shares of the company were exchanged, compared to its average volume of 1,367,847. ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $32.59. The company's fifty day moving average price is $15.72 and its 200 day moving average price is $16.07. The company has a market cap of $2.88 billion, a price-to-earnings ratio of 22.15 and a beta of 0.40.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.06. The business had revenue of $250.40 million during the quarter, compared to analyst estimates of $248.83 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. ACADIA Pharmaceuticals's quarterly revenue was up 18.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.40) EPS. As a group, sell-side analysts anticipate that ACADIA Pharmaceuticals will post 0.73 earnings per share for the current fiscal year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.